XPD K751Q

  • Product Reviews (0)
  • Citations (2)

Research Focus

Reduced DNA repair capacity resulting from genetic polymorphisms of various DNA repair genes has been associated in research studies with improved survival using platinum-based chemotherapy. Reserach suggests that reduced efficacy of the XRCC3 protein, a consequence of the polymorphic variant, may result in impaired ability to repair cisplatin DNA damage.

Target Disease/Application

DNA repair genes polymorphisms

Assay ID dbSNP ID Location Gene Symbol Gene Name SNP Type  
C___3145033_10 rs13181 Chr.19: 45854919 ERCC2 excision repair cross-complementing rodent repair deficiency, complementation group 2 Mis-sense Mutation
KLC3 kinesin light chain 3 Mis-sense Mutation, Transition Substitution

Specifications

General Specifications

# of assays: 1
Technology: TaqMan® Assays - Pre-formulated assay (20x or 60x mix)
Scale: Available in multiple scales
Intended Use: Research Use Only

Kit Storage

-20° C

 

Citations & References (2)

  • XPD and XRCC1 Genetic Polymorphisms Are Prognostic Factors in Advanced Non—Small-Cell Lung Cancer Patients Treated With Platinum Chemotherapy

Authors
Sarada Gurubhagavatula et al.
Journal
Journal of Clinical Oncology, Vol 22, No 13 (July 1), 2004: pp. 2594-2601
  • Polymorphisms in DNA repair genes modulate survival in cisplatin/gemcitabine-treated non-small-cell lung cancer patients

Authors
de las Penas et al.
Journal
Annals of Oncology 17: 668–675, 2006 R.